Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
EMERYVILLE, Calif., March 02, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.
| Thursday, March 9th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 877-675-4750 |
| International: | 719-325-4867 |
| Conference ID: | 1061121 |
| Webcast: | http://public.viavid.com/index.php?id=122985 |
| Replays, available through March 23, 2017: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 1061121 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
